This article is more than 5 years old. Information may no longer be current.
Top oncology stories: Bluetooth devices may carry cancer risk, early-onset colorectal cancer clinically differs from late-onset
Click Here to Manage Email Alerts
The top stories in oncology last week included a warning by scientists that wireless, Bluetooth devices may carry cancer risk and study findings that demonstrated that early-onset colorectal cancer is clinically and molecularly distinct from late-onset disease.
Other popular stories included research that suggested that gene expression patterns help identify patients with high-risk chronic lymphocytic leukemia, as well as meeting news from the Miami Breast Cancer Conference that found that work is “not yet done” in management of HER2-positive breast cancer and that alpelisib prolongs progression-free survival in a breast cancer subset.
Scientists warn wireless, Bluetooth devices may carry cancer risk
A group of 250 scientists has signed a petition to the United Nations and WHO expressing “serious concern” regarding the health risks associated with electromagnetic fields emitted by wireless devices. Read more.
Early-onset colorectal cancer clinically, molecularly distinct from late-onset disease
Early-onset colorectal cancer appears to have different clinical and genetic characteristics than colorectal cancer diagnosed later in life, according to results of a retrospective study published in Cancer. Read more.
Gene expression patterns identify high-risk chronic lymphocytic leukemia
A 290-gene expression signature and IGHV mutation status stratified patients with chronic lymphocytic leukemia to identify those with high-risk disease who might benefit from prompt initiation of therapy, according to a study published in Frontiers in Oncology. Read more.
Work ‘not yet done’ in management of HER2-positive breast cancer
A high unmet need still exists in the treatment of HER2-positive early breast cancer, according to a presenter at Miami Breast Cancer Conference. Read more.
Alpelisib prolongs progression-free survival in breast cancer subset
The addition of alpelisib to fulvestrant significantly extended progression-free survival among certain patients with PIK3CA-mutant breast cancer, according to results of the randomized phase 3 SOLAR-1 trial presented at Miami Breast Cancer Conference. Read more.